154 related articles for article (PubMed ID: 27302552)
1. Prophylaxis of hereditary angioedema attacks: A randomized trial of oral plasma kallikrein inhibition with avoralstat.
Aygören-Pürsün E; Magerl M; Graff J; Martinez-Saguer I; Kreuz W; Longhurst H; Nasr I; Bas M; Straßen U; Fang L; Cornpropst M; Dobo S; Collis P; Sheridan WP; Maurer M
J Allergy Clin Immunol; 2016 Sep; 138(3):934-936.e5. PubMed ID: 27302552
[No Abstract] [Full Text] [Related]
2. Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study.
Riedl MA; Aygören-Pürsün E; Baker J; Farkas H; Anderson J; Bernstein JA; Bouillet L; Busse P; Manning M; Magerl M; Gompels M; Huissoon AP; Longhurst H; Lumry W; Ritchie B; Shapiro R; Soteres D; Banerji A; Cancian M; Johnston DT; Craig TJ; Launay D; Li HH; Liebhaber M; Nickel T; Offenberger J; Rae W; Schrijvers R; Triggiani M; Wedner HJ; Dobo S; Cornpropst M; Clemons D; Fang L; Collis P; Sheridan WP; Maurer M
Allergy; 2018 Sep; 73(9):1871-1880. PubMed ID: 29688579
[TBL] [Abstract][Full Text] [Related]
3. Safety, pharmacokinetics, and pharmacodynamics of avoralstat, an oral plasma kallikrein inhibitor: phase 1 study.
Cornpropst M; Collis P; Collier J; Babu YS; Wilson R; Zhang J; Fang L; Zong J; Sheridan WP
Allergy; 2016 Dec; 71(12):1676-1683. PubMed ID: 27154593
[TBL] [Abstract][Full Text] [Related]
4. Berotralstat: First Approval.
Lee A
Drugs; 2021 Feb; 81(3):405-409. PubMed ID: 33646555
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of vascular permeability by antisense-mediated inhibition of plasma kallikrein and coagulation factor 12.
Bhattacharjee G; Revenko AS; Crosby JR; May C; Gao D; Zhao C; Monia BP; MacLeod AR
Nucleic Acid Ther; 2013 Jun; 23(3):175-87. PubMed ID: 23582057
[TBL] [Abstract][Full Text] [Related]
6. Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema.
Aygören-Pürsün E; Bygum A; Grivcheva-Panovska V; Magerl M; Graff J; Steiner UC; Fain O; Huissoon A; Kinaciyan T; Farkas H; Lleonart R; Longhurst HJ; Rae W; Triggiani M; Aberer W; Cancian M; Zanichelli A; Smith WB; Baeza ML; Du-Thanh A; Gompels M; Gonzalez-Quevedo T; Greve J; Guilarte M; Katelaris C; Dobo S; Cornpropst M; Clemons D; Fang L; Collis P; Sheridan W; Maurer M; Cicardi M
N Engl J Med; 2018 Jul; 379(4):352-362. PubMed ID: 30044938
[TBL] [Abstract][Full Text] [Related]
7. Ecallantide: a plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema.
Stolz LE; Horn PT
Drugs Today (Barc); 2010 Aug; 46(8):547-55. PubMed ID: 20830315
[TBL] [Abstract][Full Text] [Related]
8. A new oral kallikrein inhibitor for long-term prophylaxis of hereditary angioedema.
Doña I; Torres MJ
Allergy; 2021 Jun; 76(6):1619-1620. PubMed ID: 33641193
[No Abstract] [Full Text] [Related]
9. Update on therapeutic developments for hereditary angioedema.
Christiansen SC; Zuraw BL
Allergy Asthma Proc; 2009; 30(5):500-5. PubMed ID: 19843404
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis.
Banerji A; Busse P; Shennak M; Lumry W; Davis-Lorton M; Wedner HJ; Jacobs J; Baker J; Bernstein JA; Lockey R; Li HH; Craig T; Cicardi M; Riedl M; Al-Ghazawi A; Soo C; Iarrobino R; Sexton DJ; TenHoor C; Kenniston JA; Faucette R; Still JG; Kushner H; Mensah R; Stevens C; Biedenkapp JC; Chyung Y; Adelman B
N Engl J Med; 2017 Feb; 376(8):717-728. PubMed ID: 28225674
[TBL] [Abstract][Full Text] [Related]
11. Current treatment of hereditary angioedema: An update on clinical studies.
Banerji A
Allergy Asthma Proc; 2010; 31(5):398-406. PubMed ID: 20929607
[TBL] [Abstract][Full Text] [Related]
12. Current drugs in early development for hereditary angioedema: potential for effective treatment.
Bork K
Expert Opin Investig Drugs; 2014 Jul; 23(7):887-91. PubMed ID: 24797354
[TBL] [Abstract][Full Text] [Related]
13. Complement, Kinins, and Hereditary Angioedema: Mechanisms of Plasma Instability when C1 Inhibitor is Absent.
Kaplan AP; Joseph K
Clin Rev Allergy Immunol; 2016 Oct; 51(2):207-15. PubMed ID: 27273087
[TBL] [Abstract][Full Text] [Related]
14. Lanadelumab for the treatment of hereditary angioedema.
Wu MA
Expert Opin Biol Ther; 2019 Dec; 19(12):1233-1245. PubMed ID: 31657963
[No Abstract] [Full Text] [Related]
15. Prophylactic therapy in children with hereditary angioedema.
Farkas H; Csuka D; Zotter Z; Varga L; Füst G
J Allergy Clin Immunol; 2013 Feb; 131(2):579-82.e1-2. PubMed ID: 23014586
[No Abstract] [Full Text] [Related]
16. Lanadelumab for the prevention of hereditary angioedema attacks: A real-world UK audit.
Dorr AD; Chopra C; Coulter TI; Dempster J; Dziadzio M; El-Shanawany T; Garcez T; Gompels M; Herriot R; Jain R; Levi M; Lorenzo L; Makki I; Mapazire E; Murng SHK; Noorani S; Savic S; Steele CL; Symons C; Tarzi M; Yong PFK; Kiani-Alikhan S
Allergy; 2023 May; 78(5):1369-1371. PubMed ID: 36510404
[No Abstract] [Full Text] [Related]
17. Pathogenesis of Hereditary Angioedema: The Role of the Bradykinin-Forming Cascade.
Kaplan AP; Joseph K
Immunol Allergy Clin North Am; 2017 Aug; 37(3):513-525. PubMed ID: 28687106
[TBL] [Abstract][Full Text] [Related]
18. A novel assay to diagnose hereditary angioedema utilizing inhibition of bradykinin-forming enzymes.
Joseph K; Bains S; Tholanikunnel BG; Bygum A; Aabom A; Koch C; Farkas H; Varga L; Ghebrehiwet B; Kaplan AP
Allergy; 2015 Jan; 70(1):115-9. PubMed ID: 25186184
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human C1 esterase inhibitor for the treatment of hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE).
Sabharwal G; Craig T
Expert Rev Clin Immunol; 2015 Mar; 11(3):319-27. PubMed ID: 25669442
[TBL] [Abstract][Full Text] [Related]
20. The bradykinin-forming cascade and its role in hereditary angioedema.
Kaplan AP; Joseph K
Ann Allergy Asthma Immunol; 2010 Mar; 104(3):193-204. PubMed ID: 20377108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
